ACDx utilizes new imaging agents to radiolabel albumin and when used in combination with state-of-the art imaging techniques, allows for detection of albumin uptake and distribution in the patient's tumor. Since the LADR™ drug candidates are albumin-binding drugs, the Company believes the response rates will be higher in the selected patients who test positive with this personalized medicine companion diagnostic.
"Our companion diagnostic will offer physicians the ability to determine a cancer patient's unique physiological tumor characteristics and to use these distinctions to select albumin-based LADR™ drug candidates that increase the likelihood of a successful outcome, while reducing the potential for possible adverse reactions," said
The Company believes this is a significant step forward for the attractiveness of its pipeline and drug development program. "In the rapidly-evolving field of oncology, extensive resources are being devoted not only to the discovery and development of innovative drug regimens, but also to companion diagnostics to provide targeted therapies that better serve individual patients," said
Centurion BioPharma Corporation is focused on advancing a portfolio of novel, anti-cancer drug candidates that employ its LADR™ (Linker Activated Drug Release) technology, a discovery engine designed to leverage the Company's expertise in albumin biology and linker technology for the development of a new class of potential breakthrough anti-cancer therapies. A critical element of the LADR™ platform is its ability to bind anti-cancer molecules to albumin, the most ubiquitous protein in human blood plasma, and then to release the highly potent cytotoxic payload at the tumor site. This technology allows for the delivery of higher doses of drug directly to the tumor, while avoiding much of the off-target toxicity observed with the parent molecules. Centurion BioPharma's website is www.centurionbiopharma.com.
This press release contains forward-looking statements. Such statements involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks and uncertainties relating to the ability of NantCell, Inc., to obtain regulatory approval for its products that use aldoxorubicin; the ability of NantCell, Inc., to manufacture and commercialize products or therapies that use aldoxorubicin; the amount, if any, of future milestone and royalty payments that we may receive from NantCell, Inc.; Centurion BioPharma Corporation's ability to develop new ultra-high potency drug candidates based on its LADR™ technology platform; our ability to attract potential licensees; and other risks and uncertainties described in the most recent annual and quarterly reports filed by CytRx with the Securities and Exchange Commission and current reports filed since the date of CytRx's most recent annual report. All forward-looking statements are based upon information available to CytRx on the date the statements are first published. CytRx undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact: